Article

Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report

Department of Pathobiology, Cleveland Clinic, Cleveland, Ohio, USA.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.99). 12/2010; 182(12):1554-62. DOI: 10.1164/rccm.201006-0869WS
Source: PubMed

ABSTRACT The Division of Lung Diseases of the National Heart, Lung, and Blood Institute, with the Office of Rare Diseases Research, held a workshop to identify priority areas and strategic goals to enhance and accelerate research that will result in improved understanding of the lung vasculature, translational research needs, and ultimately the care of patients with pulmonary vascular diseases. Multidisciplinary experts with diverse experience in laboratory, translational, and clinical studies identified seven priority areas and discussed limitations in our current knowledge, technologies, and approaches. The focus for future research efforts include the following: (1) better characterizing vascular genotype-phenotype relationships and incorporating systems biology approaches when appropriate; (2) advancing our understanding of pulmonary vascular metabolic regulatory signaling in health and disease; (3) expanding our knowledge of the biologic relationships between the lung circulation and circulating elements, systemic vascular function, and right heart function and disease; (4) improving translational research for identifying disease-modifying therapies for the pulmonary hypertensive diseases; (5) establishing an appropriate and effective platform for advancing translational findings into clinical studies testing; and (6) developing the specific technologies and tools that will be enabling for these goals, such as question-guided imaging techniques and lung vascular investigator training programs. Recommendations from this workshop will be used within the Lung Vascular Biology and Disease Extramural Research Program for planning and strategic implementation purposes.

Download full-text

Full-text

Available from: Mark R Nicolls, Aug 31, 2015
0 Followers
 · 
206 Views
 · 
63 Downloads
  • Source
    • "The increase in the pulmonary vascular resistance is now also attributed to the structural alterations of the pulmonary arteries and reversal of these structural changes has become a treatment goal [2]. Successful and permanent reversal of the pulmonary arterial remodeling will likely require a detailed knowledge of the altered microenvironment of the remodeled pulmonary artery [2]. The early phase of lung vessel disease development in human PAH remains unexamined and it is not feasible to serially study diseased human lungs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Successful curative treatment of severe pulmonary arterial hypertension with luminal obliteration will require a thorough understanding of the mechanism underlying the development and progression of pulmonary vascular lesions. But the cells that obliterate the pulmonary arterial lumen in severe pulmonary arterial hypertension are incompletely characterized. The goal of our study was to evaluate whether inhibition of CXC chemokine receptor 4 will prevent the accumulation of c-kit(+) cells and severe pulmonary arterial hypertension. We detected c-kit(+-) cells expressing endothelial (von Willebrand Factor) or smooth muscle cell/myofibroblast (α-smooth muscle actin) markers in pulmonary arterial lesions of SU5416/chronic hypoxia rats. We found increased expression of CXC chemokine ligand 12 in the lung tissue of SU5416/chronic hypoxia rats. In our prevention study, AMD3100, an inhibitor of the CXC chemokine ligand 12 receptor, CXC chemokine receptor 4, only moderately decreased pulmonary arterial obliteration and pulmonary hypertension in SU5416/chronic hypoxia animals. AMD3100 treatment reduced the number of proliferating c-kit(+) α-smooth muscle actin(+) cells and pulmonary arterial muscularization and did not affect c-kit(+) von Willebrand Factor(+) cell numbers. Both c-kit(+) cell types expressed CXC chemokine receptor 4. In conclusion, our data demonstrate that in the SU5416/chronic hypoxia model of severe pulmonary hypertension, the CXC chemokine receptor 4-expressing c-kit(+) α-smooth muscle actin(+) cells contribute to pulmonary arterial muscularization. In contrast, vascular lumen obliteration by c-kit(+) von Willebrand Factor(+) cells is largely independent of CXC chemokine receptor 4.
    PLoS ONE 02/2014; 9(2):e89810. DOI:10.1371/journal.pone.0089810 · 3.23 Impact Factor
  • Source
    • "Medical treatment of pediatric PH has been challenging due to a lack of accessible, noninvasive, objective measures that can aid in managing these patients [2]. Specifically, there is a need for better tools for prognosis and assessment of the progression of the disease [1] [3] [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Management of pediatric pulmonary hypertension (PH) remains challenging. We have assessed a panel of circulating proteins in children with PH to investigate their value as predictive and/or prognostic biomarkers. From these determinations, we aim to develop a practical, non-invasive tool to aid in the management of pediatric PH. Methods. Twelve cytokines and growth factors putatively associated with lung or vascular disease were examined in plasma specimens from 70 children with PH using multiplex protein array technology. Associations between hemodynamics, adverse events and protein markers were evaluated. Results. Epidermal growth factor (EGF) and IL-6 were associated with important hemodynamics. Of the twelve proteins, VEGF and IL-6 were significantly, univariately associated with the occurrence of an adverse event, with odds ratios (95% confidence intervals) of 0.56 (0.33-0.98) and 1.69 (1.03-2.77), respectively. When hemodynamic predictors were combined with protein markers, the ability to predict adverse outcomes within the following year significantly increased. Conclusions. Specific circulating proteins are associated with hemodynamic variables in pediatric PH. If confirmed in additional cohorts, measurement of these proteins could aid patient care and design of clinical trials by identifying patients at risk for adverse events. These findings also further support a role for inflammation in pediatric PH.
    Mediators of Inflammation 01/2013; In press. · 3.24 Impact Factor
  • Source
    • "Medical treatment of pediatric PH has been challenging due to a lack of accessible, noninvasive, objective measures that can aid in managing these patients [2]. Specifically, there is a need for better tools for prognosis and assessment of the progression of the disease [1] [3] [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Management of pediatric pulmonary hypertension (PH) remains challenging. We have assessed a panel of circulating proteins in children with PH to investigate their value as predictive and/or prognostic biomarkers. From these determinations, we aim to develop a practical, noninvasive tool to aid in the management of pediatric PH. Methods. Twelve cytokines and growth factors putatively associated with lung or vascular disease were examined in plasma specimens from 70 children with PH using multiplex protein array technology. Associations between hemodynamics, adverse events, and protein markers were evaluated. Results. Epidermal growth factor (EGF) and IL-6 were associated with important hemodynamics. Of the twelve proteins, VEGF and IL-6 were significantly, univariately associated with the occurrence of an adverse event, with odds ratios (95% confidence intervals) of 0.56 (0.33-0.98) and 1.69 (1.03-2.77), respectively. When hemodynamic predictors were combined with protein markers, the ability to predict adverse outcomes within the following year significantly increased. Conclusions. Specific circulating proteins are associated with hemodynamic variables in pediatric PH. If confirmed in additional cohorts, measurement of these proteins could aid patient care and design of clinical trials by identifying patients at risk for adverse events. These findings also further support a role for inflammation in pediatric PH.
    Mediators of Inflammation 12/2012; 2012:143428. DOI:10.1155/2012/143428 · 3.24 Impact Factor
Show more